Market Cap : 2.17 B | Enterprise Value : 2.13 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics's book value per share for the quarter that ended in Mar. 2022 was $-1.27.
During the past 12 months, PTC Therapeutics's average Book Value Per Share Growth Rate was -130.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -85.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -49.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of PTC Therapeutics was 40.00% per year. The lowest was -85.80% per year. And the median was -6.95% per year.
PTC Therapeutics's current price is $30.35. Its book value per share for the quarter that ended in Mar. 2022 was $-1.27. Hence, today's PB Ratio of PTC Therapeutics is .
During the past 11 years, the highest P/B Ratio of PTC Therapeutics was 2187.50. The lowest was 0.00. And the median was 5.04.
The historical data trend for PTC Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PTC Therapeutics's Book Value per Share, along with its competitors' market caps and Book Value per Share data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Book Value per Share distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Book Value per Share falls into.
PTC Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (1.4 | - | 0.0) | / | 70.8 | |
= | 0.02 |
PTC Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2022 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-90.6 | - | 0.0) | / | 71.4 | |
= | -1.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of PTC Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Zacks 2022-02-18
By Seekingalpha 2021-01-20
By Zacks 2022-02-15
By Zacks 2021-04-30
By Zacks 2021-10-28
By Zacks 2022-04-04
By Seekingalpha 2020-09-30
By Zacks 2020-10-29
By Seekingalpha 2020-10-30
By Zacks 2021-05-04
By Zacks 2021-02-25